Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT07084246
Active, not recruiting Observational

Evaluation of the Effectiveness and Safety of Rozetel Tablet in Patients After PCI: A Multi-Center Observational Study

NCT07084246 · tracked via the Priya Life Science South Korea tracker
Sponsor
GC Biopharma Corp
Phase
Observational
Started
2023-06-07
Last updated
2025-07-24

Condition(s) studied

Hypertension, Dyslipidemia

Study summary

The purpose of this study is to evaluate the effectiveness and safety of the investigational drug on blood pressure and LDL cholesterol control during the observation period in patients who have undergone percutaneous coronary intervention (PCI) in actual clinical practice.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * 1\. Adults aged 19 years and older, both male and female. 2. Patients who have undergone percutaneous coronary intervention (PCI) and are receiving antihypertensive and dyslipidemia-related medications. 3\. Individuals who require the administration of the investigational product based on the investigator's medical judgment in accordance with approved indications. 4\. Individuals who can understand the information provided to them and are able to voluntarily sign the informed consent form. Exclusion Criteria: * 1\. Individuals who fall under the contraindications for administration according to the approved indications of the investigational product. 2\. Individuals who have a history of receiving the investigational product prior to participation in this study. 3\. Individuals whom the investigator deems unsuitable for participation in this observational study for any other reason.

Primary outcome measure(s)

  • The proportion of participants who meet the treatment goals for BP and LDL-C — From enrollment to the end of treatment at 24 weeks

Trial sites (1)

FacilityCityRegionStatus
GC Biopharma Yongin South Korea

More GC Biopharma Corp trials in South Korea

A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease Recruiting
A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ Active, not recruiting
Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA) Active, not recruiting
A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults Recruiting
A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07084246 on ClinicalTrials.gov ↗ ← All trials in South Korea